☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Malignant Tumors
Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab- biosimilar) from NMPA (CFDA) to Treat NSCLC
January 29, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.